Marrone Bio’s Next-Generation Nematicide/Insecticide Demonstrates Improved Levels of Crop Protection and Yield
December 16 2019 - 8:31AM
Marrone Bio (NASDAQ: MBII) (MBI), an international leader in
sustainable bioprotection and plant health solutions, today
announced the results of new U.S. field trials of its
next-generation nematicide/insecticide, which showed superior
control of yield-robbing insects and nematodes in corn.
Research trials conducted
at six Midwest locations confirmed higher yields and
cost-effective control of insects and nematodes equivalent to or
better than current industry chemical standards. This
next-generation product is derived from Burkholderia rinojensis - a
new species of soil bacterium discovered by MBI - and provides
increased performance and greater ease of use at lower rates. The
2019 trials showed outstanding control against corn rootworm
larvae, seed corn maggot and lesion nematode in field corn.
Marrone Bio currently markets soil treatment
products in the United States through its distribution partners
under the brand name Majestene® for a variety of specialty crops
including potatoes, strawberries, tobacco, cucurbits and fruiting
vegetables. The next-generation nematicide/insecticide has the
potential to expand the company’s offering to corn growers as part
of their integrated pest management systems. U.S. farmers
planted more than 90 million acres of corn in
2019, according to the National Agricultural Statistics
Service.
“Our latest field trials underscored the
performance advantages of our next-generation
insecticide/nematicide for three of the most pervasive pests in
corn,” said Kevin Hammill, chief commercial officer of Marrone Bio
Innovations. “This gives us the potential to offer new options to
our customers who are looking for high-performing, sustainable and
cost-effective solutions to control these persistent yield-robbing
insects in corn. This new product offering will expand our robust
portfolio of seed, foliar and soil treatments, and enhance our
market presence in row crops.”
“These results speak to our ability to continue
to mine and add value from our rich portfolio of microbes, cost
effectively leveraging the capital invested in our R&D
pipeline,” added Dr. Pamela Marrone, founder and chief executive
officer of Marrone Bio Innovations. “With this new product, we want
to provide growers a breakthrough sustainable alternative that will
provide greater efficacy while supporting their regenerative
agriculture growing practices.”
The current Majestene product provides effective
insect and nematode control while reducing damage to crops,
resulting in higher yields. When in contact with Majestene,
nematodes in the soil stop moving after 24 hours and die within
48-to-72 hours. Research studies also have shown that Majestene
remains in the roots and has a positive effect on fine-hair root
development.
2019 U.S. Soil Treatment Trial
Results
Six studies in the United States compared the
next-generation solution for nematode and insect control with
Majestene and current chemical treatments. This improved
nematicide/insecticide version was extremely effective in soil
treatments and demonstrated a positive yield improvement when rates
were increased, particularly when compared with commercial
standards. The current Majestene product also showed improved
control and yields, equivalent to or better than the untreated
control and current industry chemical standards. The
next-generation product is in the final phases of the R&D
process and will be submitted for regulatory approval within the
next year.
About Marrone Bio
InnovationsMarrone Bio Innovations Inc. (NASDAQ: MBII) is
a growth-oriented company leading the movement to more a
sustainable world through the discovery, development and sale of
innovative biological products for crop protection, plant health
and waterway systems treatment that help customers operate more
sustainably while increasing their return on investment. MBI has
screened over 18,000 microorganisms and 350 plant extracts,
leveraging its in-depth knowledge of plant and soil microbiomes
enhanced by advanced molecular technologies and natural product
chemistry to rapidly develop seven product lines. Supported by a
robust portfolio of over 400 issued and pending patents, MBI’s
currently available commercial products are Regalia®, Stargus®,
Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® Jet
Oxide® and Jet Ag® and Zequanox®, with a breakthrough bioherbicide
and biofumigant in the Company’s product pipeline. Pro Farm, MBI’s
Finland-based subsidiary, employs a proprietary technology derived
from wood waste to stimulate plant growth and improve plant health,
resulting in improved yields and crop quality. Products include
UBP-110®, LumiBio™, LumiBio Valta™, LumiBio Kelta™, Foramin®.
Learn more about Marrone Bio Innovations at
www.marronebio.com. We also use our investor relations website,
https://investors.marronebio.com, as well as our corporate Twitter
account, @Marronebio, as means of disclosing material non-public
information, and encourage our investors and others to monitor and
review the information we make public in these locations. Follow us
on social media: Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Forward Looking
StatementsThis press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding strategy, future operations and plans,
including assumptions underlying such statements, are
forward-looking statements, and should not be relied upon as
representing MBI’s views as of any subsequent date. Such
forward-looking statements are based on information available to
the Company as of the date of this release and involve a number of
risks and uncertainties, some beyond the Company’s control, that
could cause actual results to differ materially from those
anticipated by these forward-looking statements, including the
potential of Majestene and new versions of Majestene, the potential
of new revenue generating activities, weather, regulatory and other
factors affecting demand for the MBI’s products, any difficulty in
marketing MBI’s products in its target markets, competition in the
market for pest management products, lack of understanding of
bio-based pest management products by customers and growers.
Additional information that could lead to material changes in MBI’s
performance is contained in its filings with the SEC. MBI is under
no obligation to, and expressly disclaims any responsibility to,
update or alter forward-looking statements contained in this
release, whether as a result of current information, future events
or otherwise.
Marrone Bio Innovations
Contact:Kevin Hammill, Chief Commercial
Officerinfo@marronebio.com1-530-750-2800
Investor Relations Contact:Greg
Falesnik, Managing DirectorMZ Group – MZ North AmericaMain:
949-385-6449MBII@mzgroup.uswww.mzgroup.us
A photo accompanying this announcement is
available
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2c5c3296-8fc8-46e7-8d83-86612c5fe9d6
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024